Brochure
Extracellular vesicles (EVs) are involved in the pathogenesis of many diseases, including cancer development and neurodegeneration. Although their application in liquid biopsy is promising, there are several challenges in EV research and applications as the EV populations are very heterogeneous and the targets of interest are often in low abundance. Appropriate biomarker choice is also critical in enabling selective isolation of disease-specific EVs. These challenges and limited sensitivity in many conventional protein detection methods have impacted how EVs can be utilized effectively in patient diagnosis and monitoring. This summary provides insight on the application of Simoa® technology in EV research, such as the direct measurement of EVs from patient plasma samples targeting tetraspanins (i.e., CD9, CD63, and CD81) and tumor-derived biomarkers (EpCAM, PD-L1). We will also show that EV-derived biomarkers can be successfully profiled using Simoa. Here, we demonstrate the suitability and potential of the Simoa technology in EV-based biomarker discovery and diagnostic applications.
Related Posts
Mapping the Tau Cascade: New Insights from p-Tau 205 and p-Tau 212 for Disease Staging and Monitoring
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…